

RESEARCH ARTICLE

Open Access



Inhibition of *Staphylococcus aureus* biofilm by *Lactobacillus* isolated from fine cocoa

Tauá Alves Melo¹, Thalís Ferreira dos Santos¹, Milena Evangelista de Almeida¹, Luiz Alberto Gusmão Fontes Junior¹, Ewerton Ferraz Andrade², Rachel Passos Rezende¹, Lucas Miranda Marques² and Carla Cristina Romano^{1*}

Abstract

Background: Biofilm production represents an important virulence and pathogenesis factor for *Staphylococcus aureus*. The formation of biofilms on medical devices is a major concern in hospital environments, as they can become a constant source of infection. Probiotic bacteria, such as *Lactobacillus fermentum* and *L. plantarum*, have been found to inhibit biofilm formation; however little is known about the underlying mechanism. In this study, we tested the activity of supernatants produced by *L. fermentum* TCUESC01 and *L. plantarum* TCUESC02, isolated during the fermentation of fine cocoa, against *S. aureus* CCMB262 biofilm production. We measured inhibition of biofilm formation in vitro and analyzed biofilm structure by confocal and electronic microscopy. Additionally, we quantified the expression of *S. aureus* genes *icaA* and *icaR* involved in the synthesis of the biofilm matrix by real-time PCR.

Results: Both *Lactobacillus* supernatants inhibited *S. aureus* growth. However, only *L. fermentum* TCUESC01 significantly reduced the thickness of the biofilm, from 14 μm to 2.83 μm (at 18 mg mL^{-1} , 90 % of the minimum inhibitory concentration, MIC), 3.12 μm (at 14 mg mL^{-1} , 70 % of the MIC), and 5.21 μm (at 10 mg mL^{-1} , 50 % of the MIC). Additionally, *L. fermentum* TCUESC01 supernatant modulated the expression of *icaA* and *icaR*.

Conclusions: *L. fermentum* TCUESC01 reduces the formation of *S. aureus* biofilm under subinhibitory conditions. Inhibition of biofilm production probably depends on modulation of the *ica* operon.

Keywords: Antistaphylococcal, Biofilm, *ica*, *Lactobacillus fermentum*, Probiotic properties

Background

Staphylococcus aureus is a widely distributed and opportunistic human pathogen. It is the causative agent of both simple skin infections and potentially life-threatening systemic complications such as toxic shock syndrome [1]. *S. aureus* is a major concern in hospital environments because asymptomatic carriers represent a great risk factor to patients subjected to long hospitalization periods [2].

Some aspects of *S. aureus* pathogenicity are related to biofilm production, which increases resistance to chemotherapeutic treatments and to the host's defense mechanisms [3]. The biofilm is composed of cells adhering to a surface and held together by a polymer matrix. The main components of the matrix are polysaccharides, proteins, and extracellular DNA (eDNA) [4].

S. aureus secretes polysaccharides of intercellular adhesion (PIAs), which are composed mostly of β -1, 6-*N*-acetylglucosamine residues. PIA production and excretion is controlled by the *icaADBC* operon [5]. *icaA*, the first gene to be transcribed, leads to production of short chains of *N*-acetylglucosamine oligomers [6]. *icaD*, co-expressed with *icaA*, enhances oligomer production by about 20 fold [7, 8]. *icaC* is responsible for increasing oligomer chains and possibly for translocation to the cell surface [8, 9]. Finally, *icaB* is thought to deacetylate poly-*N*-acetylglucosamines [9]. The *icaADBC* locus is regulated by a transcriptional repressor located upstream encoded by *icaR* [10]. This repressor protein can bind to the *ica operon* promoter region close to the *icaA* start codon [8]. Additional factors that can negatively influence the *ica operon* in *S. aureus* include expression of the weak repressor *TcaR*, global regulation by *SarA*, and the insertion sequence element IS256 in the *ica* locus [8, 11]. The *ica operon* is also regulated by environmental

* Correspondence: romanocc@uol.com.br

¹Department of Biological Sciences, Santa Cruz State University, Ilhéus-Itabuna Road, km 16 Salobrinho, Ilhéus 45662-900, Bahia State, Brazil
Full list of author information is available at the end of the article



factors, which play an important role in the response to anaerobic growth (*SrrAB*), in the response to stress (*Spx*), supplementation with glucose or ethanol, osmolarity, temperature, and low concentrations of antibiotics [8, 11, 12]. Another way of controlling this operon is through a regulatory protein responsible for biofilm formation, *Rbf*, which can repress transcription of *IcaR* and indirectly increase expression of the gene *icaADBC* [11].

S. aureus biofilms are commonly treated with antibiotics, such as protein synthesis inhibitors that target the cell membrane and cell wall, as well as inhibitors of DNA and RNA synthesis [4], or antimicrobials like Cu^{2+} that lead to cell membrane breakage and subsequent cell lysis [13]. The indiscriminate use of antibiotics for the treatment of bacterial infections has been suggested to be responsible for the appearance of multidrug-resistant bacteria such as methicillin-resistant *S. aureus* strains [14]. In this context, alternatives to antibiotic therapy are more than welcome. Probiotics represent a possible option, as the microorganisms that produce them have been proven effective in the prevention and control of human pathogens [15].

Lactobacillus fermentum TCUESC01 and *L. plantarum* TCUESC02 strains have been recently isolated from the fermentation of fine cocoa seeds. Our group has demonstrated their anti-inflammatory potential and technological properties. We observed that these strains exhibited probiotic characteristics in vivo in an experimental colitis model, reducing histological damage and the systemic concentration of inflammatory cytokines. Additionally, they inhibited the growth of pathogenic bacteria and displayed high resistance to the stressful conditions of the gastrointestinal tract and industrial environments (unpublished observations). In this study, we evaluated the activity of cell-free supernatant from *L. fermentum* TCUESC01 and *L. plantarum* TCUESC02 on *S. aureus* CCMB262 biofilm formation.

Methods

Microorganisms and culture conditions

Pure cultures of *L. fermentum* TCUESC01, *L. plantarum* TCUESC02, and *S. aureus* CCMB262 were used. TCUESC01 and TCUESC02 strains were previously isolated by our group during fine cocoa fermentation [16]. The cultures were stored at $-80\text{ }^{\circ}\text{C}$ in 10 % skim milk (Molico®, Nestlé, São Paulo Brazil) with 30 % glycerol. Lactobacilli were cultured in de Man, Rogosa, and Sharpe (MRS) broth (1 % peptone, 0.8 % meat extract, 0.4 % yeast extract, 2 % glucose, 0.5 % sodium acetate, 0.2 % dipotassium hydrogen phosphate, 0.02 % magnesium sulfate heptahydrate, 0.005 % manganese sulfate tetrahydrate, 0.02 % triammonium citrate) (HiMedia®, Mumbai, India), for 48 h at $37\text{ }^{\circ}\text{C}$. Species identity was confirmed by 16S rDNA sequencing and strains were deposited in the GenBank

database [17] under accession numbers KU244478 and KU244476.

S. aureus CCMB262 was obtained from the Microorganisms Culture Collection of Bahia (CCMB), Brazil. The strain, which is resistant to streptomycin and dihydrostreptomycin, was cultured in tryptic soy broth (TSB; DIFCO, Becton Dickinson, Franklin Lakes, NJ, USA) supplemented with 1 % (w/v) glucose (Glc) at $37\text{ }^{\circ}\text{C}$ with agitation (250 rpm) for 18 h. For inoculum standardization, *S. aureus* cells were homogenized in saline solution (NaCl 0.85 %) and the suspension was diluted to 0.5×10^8 CFU·mL⁻¹ using a spectrophotometer (Evolution 60, Thermo Fisher Scientific, Waltham, MA, USA).

Supernatant preparation and lyophilization process

L. fermentum TCUESC01 and *L. plantarum* TCUESC02 were cultured in 30 mL of MRS broth. Following centrifugation at $10,000 \times g$ for 15 min at $4\text{ }^{\circ}\text{C}$, culture supernatants were collected and filtered through a $0.22\text{ }\mu\text{m}$ nitrocellulose membrane. Supernatants and samples containing medium culture only (control) were frozen at $-80\text{ }^{\circ}\text{C}$ for 24 h and lyophilized (Lyophilizer LS3000, Terroni, São Carlos, Brazil). Following lyophilization, the samples were weighed and stored at $-20\text{ }^{\circ}\text{C}$. They were then rehydrated with sterile deionized water prior to use.

Minimum inhibitory concentration (MIC) assay

MIC assays were performed by microdilution in 96-well plates (Costar®, Corning, NY, USA), in accordance with recommendations from the Clinical and Laboratory Standards Institute [18]. A serial dilution was performed starting with $40\text{ }\mu\text{g}\cdot\text{mL}^{-1}$ of TCUESC01 and TCUESC02 supernatants on Mueller Hinton (MH) medium containing 5×10^5 CFU·mL⁻¹ of *S. aureus* CCMB262 per well. The same procedure was performed with the following controls: lyophilized medium without *Lactobacillus* (MRS control); MH without inoculum (medium sterility control - MC); MH containing 5×10^5 CFU·mL⁻¹ of *S. aureus* CCMB262 (positive control); MH containing 5×10^5 CFU·mL⁻¹ of *S. aureus* CCMB262 and $12.5\text{ }\mu\text{g}\cdot\text{mL}^{-1}$ chloramphenicol (negative control). The microplate was incubated for 24 h at $37\text{ }^{\circ}\text{C}$ and revealed with 20 μL of Resazurin (0.01 %) for 30 min at $37\text{ }^{\circ}\text{C}$. At the same time, 5 μL of each suspension (samples and control) was cultured on MH agar (MHA; DIFCO) for 24 h at $37\text{ }^{\circ}\text{C}$, after which the inhibitory concentrations were classified as bactericidal or bacteriostatic. The entire experiment was performed three times with three independent repetitions.

Preparation of subinhibitory concentrations of TCUESC01 and TCUESC02 supernatants

To avoid killing all *S. aureus*, lyophilized supernatants of the two *Lactobacillus* strains were weighed and diluted to concentrations below the MIC. Thus, dilutions

were made using subinhibitory concentrations of 90, 70, and 50 % of MIC.

Biofilm formation on a polystyrene plate

The ability of *S. aureus* to form biofilms following treatment with *Lactobacillus* supernatant was analyzed according to the methodology proposed by Oliveira et al. (2014) [19]. Briefly, *S. aureus* CCMB262 was cultured in 5 mL TSB with 1 % Glc for 18 h at 37 °C under agitation (250 rpm) and treated with *Lactobacillus* supernatants (90 %, 70 %, or 50 % of the MIC) or control medium. The cultures were diluted (1:100) in the same medium, 200 µL was inoculated in a 96-well plate (Costar®), and plates were incubated at 37 °C for 24 h. The plates were washed twice with phosphate-buffered saline (PBS), dried for 1 h at 65 °C, 1 % crystal violet was added, and the plates were incubated for a further 30 min at 25 °C. Each well was washed twice with PBS and 200 µL PBS

was added prior to measuring absorbance at 492 nm (A_{492nm}) using a microplate reader (VersaMax; Molecular Devices®, Sunnyvale, CA, USA). The experiment was carried out in quadruplicate with at least two independent experiments. Biofilm production was compared to that of *Streptococcus pyogenes* ATCC75194 ($A_{492nm} = 0.07$). The biofilm formation index (BFI) was calculated as follows:

$$BFI = \frac{x}{y}$$

where x is the optical density at A_{492nm} of the biofilm and y is the optical density at A_{492nm} of *Streptococcus pyogenes* (0.07).

Based on the BFI, *S. aureus* cultures were classified as non-producers (less than or equal to zero), weak producers (less than 1), moderate producers (between




Fig. 1 a Effect of minimum inhibitory concentration (MIC) of *Lactobacillus fermentum* TCUESC01 and *L. plantarum* TCUESC02 supernatants on *Staphylococcus aureus* CCMB262 growth. MRS Control, MRS medium without lyophilized *Lactobacillus* cells; PC, positive control for *S. aureus*; NC, negative control, *S. aureus* with 12.5 µg mL⁻¹ chloramphenicol; MC, sterility control of MH medium. **b** Bactericidal/bacteriostatic activity of *L. fermentum* TCUESC01 and *L. plantarum* TCUESC02 supernatants (at MIC doses) against *S. aureus* CCMB262 grown on MHA

1 and 2), producers (between 2 and 3), or strong biofilm producers (greater than 4).

Biofilm evaluation by confocal laser scanning microscopy


S. aureus CCMB262 biofilm viability was assessed according to Hobby et al. (2012) with some modifications [20]. *S. aureus* CCMB262 was cultured in TSB with 1 % Glc for 18 h at 37 °C in 12-well culture plates (Costar®) containing 18 mm coverslips. Cells were cultured in the presence of *L. fermentum* TCUESC01 (90, 70, and 50 % of MIC) and *L. plantarum* TCUESC02 (90 and 70 % of MIC) supernatants or control medium. Microplates were incubated for 18 h at 37 °C, then coverslips were washed twice with 0.85 % NaCl and stained with 0.3 µg·mL⁻¹ 4', 6'-diamidino-2-phenylindole (DAPI; Molecular Probes, Carlsbad, CA, USA) and 2.5 µg·mL⁻¹ propidium iodide (PI; Invitrogen, Carlsbad, CA, USA) for 15 min in the dark. The coverslips were observed with a confocal laser scanning microscope (Carl Zeiss LSM 700; Jena, Germany), equipped with an argon laser at 488 nm and two helium/neon lasers at 543 nm.

Cultivation of *S. aureus* CCMB262 in the presence or absence of *L. fermentum* TCUESC01 supernatant at a subinhibitory dose (50 % of MIC)

To confirm that the concentration used to inhibit the biofilm was not lethal to *S. aureus*, a growth curve was constructed. *S. aureus* (75 µL, 0.5 × 10⁸ CFU·mL⁻¹) was inoculated in 75 mL TSB with 1 % Glc and cultivated in the presence or absence of 750 mg of TCUESC01 supernatant (50 % of MIC) for 24 h at 37 °C under agitation (250 rpm). Aliquots were collected every 4 h to record optical density at 660 nm and count CFU·mL⁻¹ in mannitol salt agar.

Phenotypic evaluation of biofilms by scanning electron microscopy (SEM)

The phenotype of *S. aureus* CCMB262 biofilm was evaluated by SEM according to Pitino et al. (2012) with some modifications [21]. *S. aureus* was cultured in TSB with 1 % Glc in the presence or absence of TCUESC01 supernatant in 12-well culture plates (Costar®) containing 18 mm coverslips. After incubation for 24 h at 37 °C, the coverslips were washed twice with 0.85 % NaCl and dehydrated with 50, 60, 70, 80, and 90 % acetone for 10 min each, and twice with 100 % acetone for 10 min. The coverslips were subsequently dehydrated in a critical point dryer CPD 030 (BAL-TEC®, Balzers, Germany) using liquid carbon dioxide as transition fluid. The samples were placed in aluminum pieces, metallized with a SCD-050 (BAL-TEC®, Alzenau, Germany), and viewed under a scanning electron microscope (Quanta 250, FEI, Hillsboro, OR, USA).



Total RNA extraction

S. aureus CCMB262 was cultured in TSB with 1 % Glc for 18 h at 37 °C under agitation (250 rpm), in the presence or absence of *L. fermentum* TCUESC01 supernatant (50 % of the MIC). The samples were then diluted in the same medium (1:100) and incubated at 37 °C for another 18 h, after which aliquots were collected and used immediately for RNA extraction.

Each sample (1 mL) was centrifuged at 10,000 × g for 10 min at 4 °C. The supernatant was discarded and RNA from the pellet was extracted with the RNAqueous® Phenol-free total RNA isolation kit (Ambion®, Waltham, MA, USA), according to the manufacturer's




Fig. 3 *S. aureus* CCMB262 growth in the presence or not of *L. fermentum* TCUESC01 supernatant at a subinhibitory dose (50 % of MIC). ● and continuous line, standard growth curve with *S. aureus* CCMB262 (control); □ and dashed line, growth curve of *S. aureus* CCMB262 with addition of *L. fermentum* TCUESC01 supernatant at 50 % of the MIC (10 mg mL⁻¹). The result represents the average of three experiments

recommendations. The RNA was visualized on a 1 % agarose gel and quantified with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific).

Reverse transcription, PCR, and real-time PCR

cDNA was synthesized using 25 mg RNA and the SuperScript™ First-Strand Synthesis System for RT-PCR kit (Invitrogen) following the manufacturer's protocol. Specific primers (Invitrogen) were selected according to Yu et al. (2012) [22]: *icaR* Forward (5'-ATCTAATACGCCTGAGGA-3'), Reverse (5'-TTCTTCCACTGCTCCAA-3'); *icaA* Forward (5'-TTTCGGGTGTCTTCACTCTAT-3'), Reverse (5'-CGTAGTAATACTTCGTGTCCC-3'); *16S rRNA S. aureus* Forward (5'-CGTGGAGGGTCATTGGA-3'), Reverse (5'-CGTTTACGGCGTGGACT-3'). Amplification was carried out in a Mastercycler Gradient Nexus

Thermal Cycler (Eppendorf, Hauppauge, NY, USA). The cDNA was then quantified with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific).

Gene expression analysis was carried out on a 7500 Fast real-time PCR system (Applied Biosystems, Waltham, MA, USA), using 10 ng cDNA and the KAPA SYBR® qPCR Master Mix ABI Prism™ kit (Kapa Biosystems, Wilmington, MA, USA) according to the manufacturer's recommendations. The PCR reaction was carried out in quintuplicate with an initial denaturation at 95 °C for 5 min followed by 40 cycles of amplification at 95 °C for 20 s, 60 °C for 20 s, and 72 °C for 20 s. Data were normalized to *16S rRNA* (endogenous control) and the relative quantification (RQ) was calculated with 7500 Software v 2.3 (Applied Biosystems).




Fig. 4 Confocal microscopy of *S. aureus* CCMB262 treated with *L. fermentum* TCUESC01 and *L. plantarum* TCUESC02 supernatants at subinhibitory doses. Treatments were as follows: **a** untreated *S. aureus* CCMB262; **b** TCUESC02 at 90 % of the MIC (2.25 mg mL⁻¹); **c** TCUESC02 at 70 % of the MIC (1.75 mg mL⁻¹); **d** TCUESC01 at 90 % of the MIC (18 mg mL⁻¹); **e** TCUESC01 at 70 % of the MIC (14 mg mL⁻¹); **f** TCUESC01 at 50 % of the MIC (10 mg mL⁻¹). The biofilm was stained with DAPI (blue, panel 2) and PI (red, panel 3); panel 1 shows the overlapping of panels 2 and 3

Statistical analysis


Average, standard deviation, *t*-test, analysis of variance, Tukey's multiple comparison test, graphics, and other statistical analyses were performed using the Graphpad® prism 5.0 software (GraphPad Software, San Diego, CA, USA).

Results and discussion

Antimicrobial susceptibility tests revealed that the supernatant from *L. plantarum* TCUESC02 had a stronger inhibitory effect on *S. aureus* CCMB262 growth (MIC, 2.5 mg·mL⁻¹) than that of *L. fermentum* TCUESC01 (MIC, 20 mg·mL⁻¹) (Fig. 1). The potential of *Lactobacillus* species to inhibit pathogens of clinical importance such as *S. aureus* had been evaluated before. Accordingly, Al Kassaa et al. (2014) showed that *L. fermentum* CMUL054 and *L. plantarum* CMUL140 were active against *S. aureus* ATCC33862 [23]. Moreover, Hor and Liong (2014) analyzed 87 lactic acid bacteria strains and three strains of bifidobacteria, and found that all strains inhibited the growth of *S. aureus* by 0.5 to 34.2 %; *L. fermentum* and *L. plantarum*, which were isolated from milk, inhibited growth by around 20 % [24]. Although inhibition of *S. aureus* by lactic bacteria has been reported in many studies [23–26], few of them have calculated the MIC from extracellular bacterial extracts. Lactobacilli produce various secondary metabolites that exhibit antimicrobial activity, such as organic acids, ethyl alcohol, bacteriocins, hydrogen peroxide, and surfactants [15, 26–28]. The strains used in this study were isolated during cocoa fermentation, a process characterized by high temperature conditions, low oxygen concentrations, and low glucose availability. Lactobacilli are probably selected for their ability to withstand these conditions, which makes them an interesting source of compounds with biological activities of human interest.

S. aureus CCMB262 is regarded as a strong biofilm producer (BFI 17.39). After treatment with *L. fermentum* TCUESC01 supernatant, we noticed a significant reduction in the BFI ($p < 0.001$). Upon treatment with 90 % (18 mg·mL⁻¹) and 70 % of the MIC (14 mg·mL⁻¹), classification of *S. aureus* CCMB262 changed from strong to moderate biofilm producers (BFI 1.55 and 1.69 respectively); it went from strong to biofilm producer (BFI 3.3) when treated with 50 % of the MIC (10 mg·mL⁻¹) (Fig. 2).


L. plantarum TCUESC02 was less effective against *S. aureus* CCMB262 biofilm formation (MIC, 2.5 mg·mL⁻¹). We found a significant difference in the BFI only when using 90 % of the MIC ($p < 0.01$), meaning that *S. aureus* CCMB262 was still a strong biofilm producer. We did not observe statistically significant differences between treatments with 90 % (2.25 mg·mL⁻¹) or 70 % of the MIC (1.75 mg·mL⁻¹) for this strain. In a previous report, the



supernatant of *L. bulgaricus* FTDC8611 inhibited significantly *S. aureus* biofilm, an effect attributed to organic acids [24]. Also, Ait Ouali et al. (2014) demonstrated that *L. pentosus* LB3F2 had antimicrobial and antibiofilm activity against *S. aureus* SA3 [29].

A comparison between bacterial growth curves in the presence or absence of TCUESC01 supernatant at 50 % of the MIC (10 mg·mL⁻¹) revealed this concentration was not lethal to *S. aureus* CCMB262. This indicates that the decrease in biofilm formation was not caused by death of the pathogen (Fig. 3). Instead, TCUESC01 appeared to secrete a modulatory substance capable of interfering with the pathogen's capacity to form biofilms.

To confirm the results on biofilm inhibition, we visualized its structural organization by confocal microscopy






Fig. 7 Scanning electron microscopy of *S. aureus* CCMB262 biofilm treated or not with *L. fermentum* TCUESC01 supernatant. Treatments were as follows: **a** untreated control; **b** 50 % of the MIC

(Fig. 4). To this end, we used two fluorescent nucleic acid stains, DAPI and PI. DAPI penetrates the membrane of viable cells, whereas PI cannot access intact cells and only stains dead cells. The biofilm of *S. aureus* CCMB262 presented an irregular distribution of living and dead cells, with dense clusters of eDNA/dead cells. Treatment with TCUESC01 supernatant (90, 70, and 50 % of the MIC) substantially reduced *S. aureus* biomass, with a proportional decrease in both living and dead cells. A reduced amount of eDNA and/or dead cells was observed also in the biofilm of *S. aureus* treated with TCUESC02

supernatant (Fig. 5). eDNA is one of the main components of biofilms [4]. It functions as a cohesive factor between bacteria, stabilizing the overall biofilm structure [30]. Moreover, it increases resistance to antimicrobials, such as aminoglycosides [31] and vancomycin [32]. Thus, reduction of eDNA production represents a potential tool for microbial control.

Microscopy analysis revealed also a significant reduction in *S. aureus* biofilm thickness at all tested subinhibitory concentrations of *L. fermentum* TCUESC01 supernatant ($p < 0.05$). Whereas the average thickness of the biofilm in




Fig. 8 Real-time quantification of *icaA* and *icaR* expression in *S. aureus* CCMB262 treated or not with *L. fermentum* TCUESC01 supernatant. **a** Relative quantification (RQ) of *icaA*. **b** RQ of *icaR*. Treatments were as follows: 1, untreated control; 2, 50 % of the MIC. Values correspond to RQs ($2^{-\Delta\Delta CT}$) normalized to *16S rRNA*.*, statistical significance at $p < 0.05$, t-test

the control was 14 μm , samples treated with 90 % (18 $\text{mg}\cdot\text{mL}^{-1}$), 70 % (14 $\text{mg}\cdot\text{mL}^{-1}$), and 50 % (10 $\text{mg}\cdot\text{mL}^{-1}$) of the MIC presented a thickness of 2.83, 3.12, and 5.21 μm , respectively (Fig. 6). It should be noted, that TCUESC02 did not cause any significant reduction in biofilm thickness.

To visualize the intimate structure of the *S. aureus* biofilm we used SEM. Following treatment with *L. fermentum* TCUESC01 supernatant (50 % of the MIC), we noticed a decrease in the biofilm matrix (Fig. 7), suggesting possible interference with the production of PIAs.

PIA synthesis depends on the *icaADBC* locus [7]. Thus, we sought to verify whether the phenotypic modulation of *S. aureus* biofilm by *L. fermentum* TCUESC01 was related to the genetic regulation of *icaA* and *icaR* genes. We observed that treatment with *L. fermentum* supernatant (50 % of the MIC) significantly increased the expression of *S. aureus* regulator gene *icaR*. Accordingly, RQ increased from 1 (untreated) to 68.45 (treated) (Fig. 8a), while *icaA* expression dropped from a RQ of 1 (untreated) to 0.39 (treated) (Fig. 8b). These results suggest that the reduction of *S. aureus* CCMB262 biofilm upon treatment with TCUESC01 is associated with inhibition of PIA production.

Biofilms are formed by planktonic cells that bind irreversibly to a solid substrate. Wrapped in a matrix, cells multiply, differentiate, and modify gene expression patterns, in addition to creating channels for nutrient circulation [33]. After ripening, fragments of this bacterial community scatter, carrying all the “mother” community features such as antimicrobial resistance and virulence, and adhere elsewhere to repeat the cycle [34]. When organized into biofilms, bacteria tend to become more pathogenic. Suci et al. (1994) demonstrated the delayed penetration of ciprofloxacin into biofilms of *Pseudomonas aeruginosa* ERC-1 [35]. Seemingly, Ceri et al. (1999) found that the MIC of some antibiotics was around 100 to 1000 times greater for microorganisms in biofilms [36]. These findings underscore the importance of developing new strategies to combat biofilms, such as the use of probiotics. Here, *L. fermentum* TCUESC01 and *L. plantarum* TCUESC02 showed bactericidal properties against *S. aureus* CCMB262. Furthermore, TCUESC01 was able to reduce the formation of *S. aureus* biofilms under subinhibitory conditions. In addition, increased *icaR* and reduced *icaA* expression in *S. aureus* cultures treated with TCUESC01 supernatant indicated that the reduction in biofilm production occurred through modulation of the *ica* operon.

Conclusions

The results presented in this study suggest an interesting novel application for lactobacilli isolated from fine cocoa. The antimicrobial effect and biofilm inhibition exhibited by the probiotic strain TCUESC01 could be

applied to the treatment and prevention of infections with pathogenic bacterial strains.

Abbreviations

BFi: Biofilm formation index; CCMB: Microorganisms Culture Collection of Bahia; CLSI: Clinical and Laboratory Standards Institute; DAPI: 4', 6'-diamidino-2-phenylindole; eDNA: Extracellular DNA; Glc: Glucose; MC: Sterility control of the mueller hinton medium; MH: Mueller hinton; MHA: Mueller hinton agar; MIC: Minimum inhibitory concentration; MRS: de Man, Rogosa, and Sharpe; NC: Negative control; PBS: Phosphate-buffered saline; PI: Propidium iodide; PIA: Polysaccharide of intercellular adhesion; RQ: Relative quantification; RT-PCR: Real-time PCR; RZ: Resazurin; SEM: Scanning electron microscopy; TSB: Tryptic soy broth

Acknowledgments

We thank Dr. Eduardo Gross, and Lucas Ribeiro dos Santos (Centro de Microscopia Eletrônica, CME-UESC) for the technical support with confocal laser scanning microscopy and scanning electron microscopy studies. And we thank Dr. Eric de Lima Silva Marques (Laboratório de Biotecnologia Microbiana – UESC) and Dr. Sara Pereira Menezes for the technical support with Total RNA extraction and real-time PCR.

Funding

This research was supported by a grant from Fundação de Amparo a Pesquisa do Estado da Bahia (FAPESB) request number 4450/2012, Conselho de Desenvolvimento Científico e Tecnológico (CNPq) request number 408442/2013-1. FAPESB provided productivity and graduate fellowships for authors term number BOL0277/2013.

Availability of data and materials

The data generated or analysed during this study are included in this published article. Additional data available from the corresponding author on reasonable request.

Authors' contributions

TAM, TSF, RPR, LMM, CCR projected the study, assessed, and interpreted the results. TAM executed the experiments and prepared the manuscript. MEA, LAGFJ, EFA assisted in the minimum inhibitory concentration and biofilm formation index experiments. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Author details

¹Department of Biological Sciences, Santa Cruz State University, Ilhéus-Itabuna Road, km 16 Salobrinho, Ilhéus 45662-900, Bahia State, Brazil. ²Multidisciplinary Institute for Health, Federal University of Bahia, Rio de Contas Street, Candeias 17,58 Block, Vitória da Conquista 45029-094, Bahia State, Brazil.

Received: 21 July 2016 Accepted: 26 October 2016

Published online: 28 October 2016

References

- Davenport DS, Massanari RM, Pfaller MA, Bale MJ, Streed SA, Hierholzer Jr WJ. Usefulness of a test for slime production as a marker for clinically significant infections with coagulase-negative staphylococci. *J Infect Dis*. 1986;153:332–9.
- Kollef M. SMART approaches for reducing nosocomial infections in the ICU. *Chest*. 2008;134:447–56.
- Del Pozo JL, Patel R. The challenge of treating biofilm-associated bacterial infections. *Clin Pharmacol Ther*. 2007;82:204–9.
- Kiedrowski MR, Horswill AR. New approaches for treating staphylococcal biofilm infections. *Ann N Y Acad Sci*. 2011;1241:104–21.

5. Cramton SE, Gerke C, Schnell NF, Nichols WW, Götz F. The intercellular adhesion (*ica*) locus is present in *Staphylococcus aureus* and is required for biofilm formation. *Infect Immun*. 1999;67:5427–33.
6. Vasudevan P, Nair MKM, Annamalai T, Venkitanarayanan KS. Phenotypic and genotypic characterization of bovine mastitis isolates of *Staphylococcus aureus* for biofilm formation. *Vet Microbiol*. 2003;92:179–85.
7. Götz F. *Staphylococcus* and biofilms. *Mol Microbiol*. 2002;43:1367–78.
8. O'Gara JP. *ica* and beyond: biofilm mechanisms and regulation in *Staphylococcus epidermidis* and *Staphylococcus aureus*. *FEMS Microbiol Lett*. 2007;270:179–88.
9. Vuong C, Kocianova S, Voyich JM, Yao Y, Fischer ER, DeLeo FR, et al. A crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion, and virulence. *J Biol Chem*. 2004;279:54881–6.
10. Conlon KM, Humphreys H, O'Gara JP. *icaR* encodes a transcriptional repressor involved in environmental regulation of *ica* operon expression and biofilm formation in *Staphylococcus epidermidis*. *J Bacteriol*. 2002;184:4400–8.
11. Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. *Staphylococcus aureus* biofilms: properties, regulation, and roles in human disease. *Virulence*. 2011;2:445–59.
12. Agarwal A, Jain A. Glucose & sodium chloride induced biofilm production & *ica* operon in clinical isolates of staphylococci. *Indian J Med Res*. 2013;138:262–6.
13. Sun D, Xu D, Yang C, Shahzad MB, Sun Z, Xia J, Zhao J, Gu T, Yang K, Wang G. An investigation of the antibacterial ability and cytotoxicity of a novel cu-bearing 317 L stainless steel. *Sci Rep*. 2016;6:29244.
14. Grema HA, Geidam YA, Gadzama GB, Ameh JA, Suleiman A. Methicillin resistant *Staphylococcus aureus* (MRSA): a review. *Adv Anim Vet Sci*. 2015;3:79–98.
15. Charlier C, Cretenet M, Even S, Le Loir Y. Interactions between *Staphylococcus aureus* and lactic acid bacteria: an old story with new perspectives. *Int J Food Microbiol*. 2009;131:30–9.
16. Dos Santos TF, Melo TA, Santos DS, Rezende RP, Dias JCT, Romano CC. Efficacy of oral administration of lactic acid bacteria isolated from cocoa in a fermented milk preparation: reduction of colitis in an experimental rat model. *Genet Mol Res*. 2016;15(3). doi:10.4238/gmr.15028097.
17. GenBank database. <https://www.ncbi.nlm.nih.gov/>. Accessed 19 Jul 2016.
18. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard – Ninth Edition. CLSI document M07-A9. Wayne, PA: Clinical Laboratory Standards Institute; 2012.
19. Oliveira PS, Souza SG, Campos GB, da Silva DC, Sousa DS, Araújo SP, et al. Isolation, pathogenicity and disinfection of *Staphylococcus aureus* carried by insects in two public hospitals of Vitória da Conquista, Bahia, Brazil. *Braz J Infect Dis*. 2014;18:129–36.
20. Hobby GH, Quave CL, Nelson K, Compadre CM, Beenken KE, Smeltzer MS. *Quercus cerris* extracts limit *Staphylococcus aureus* biofilm formation. *J Ethnopharmacol*. 2012;144:812–5.
21. Pitino I, Randazzo CL, Cross KL, Parker ML, Bisignano C, Wickham MS, et al. Survival of *Lactobacillus rhamnosus* strains inoculated in cheese matrix during simulated human digestion. *Food Microbiol*. 2012;31:57–63.
22. Yu D, Zhao L, Xue T, Sun B. *Staphylococcus aureus* autoinducer-2 quorum sensing decreases biofilm formation in an *icaR*-dependent manner. *BMC Microbiol*. 2012;12:288. doi:10.1186/1471-2180-12-288.
23. Al Kassaa I, Hamze M, Hober D, Chihib NE, Drider D. Identification of vaginal Lactobacilli with potential probiotic properties isolated from women in north Lebanon. *Microb Ecol*. 2014;67:722–34.
24. Hor YY, Liong MT. Use of extracellular extracts of lactic acid bacteria and bifidobacteria for the inhibition of dermatological pathogen *Staphylococcus aureus*. *Dermatologica Sin*. 2014;32:141–7.
25. Heikkilä MP, Saris PEJ. Inhibition of *Staphylococcus aureus* by the commensal bacteria of human milk. *J Appl Microbiol*. 2003;95:471–8.
26. Otero MC, Nader-Macías ME. Inhibition of *Staphylococcus aureus* by H₂O₂-producing *Lactobacillus gasseri* isolated from the vaginal tract of cattle. *Anim Reprod Sci*. 2006;96:35–46.
27. Walencka E, Różalska S, Sadowska B, Różalska B. The influence of *Lactobacillus acidophilus*-derived surfactants on staphylococcal adhesion and biofilm formation. *Folia Microbiol (Praha)*. 2008;53:61–6.
28. Winkelströter LK, Tulini FL, De Martinis ECP. Identification of the bacteriocin produced by cheese isolate *Lactobacillus paraplantarum* FT259 and its potential influence on *Listeria monocytogenes* biofilm formation. *LWT - Food Sci Technol*. 2015;64:586–92.
29. Ait Ouali F, Al Kassaa I, Cudennec B, Abdallah M, Bendali F, Sadoun D, et al. Identification of lactobacilli with inhibitory effect on biofilm formation by pathogenic bacteria on stainless steel surfaces. *Int J Food Microbiol*. 2014;191:116–24.
30. Rajendran NB, Eikmeier J, Becker K, Hussain M, Peters G, Heilmann C. Important contribution of the novel locus *comEB* to extracellular DNA-dependent *Staphylococcus lugdunensis* biofilm formation. *Infect Immun*. 2015;83:4682–92.
31. Chiang W-C, Nilsson M, Jensen PØ, Højby N, Nielsen TE, Givskov M, et al. Extracellular DNA shields against aminoglycosides in *Pseudomonas aeruginosa* biofilms. *Antimicrob Agents Chemother*. 2013;57:2352–61.
32. Doroshenko N, Tseng BS, Howlin RP, Deacon J, Wharton JA, Thurner PJ, et al. Extracellular DNA impedes the transport of vancomycin in *Staphylococcus epidermidis* biofilms preexposed to subinhibitory concentrations of vancomycin. *Antimicrob Agents Chemother*. 2014;58:7273–82.
33. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. *Science*. 1999;284:1318–22.
34. Mizan MFR, Jahid IK, Ha S-D. Microbial biofilms in seafood: a food-hygiene challenge. *Food Microbiol*. 2015;49:41–55.
35. Suci PA, Mittelman MW, Yu FP, Geesey GG. Investigation of ciprofloxacin penetration into *Pseudomonas aeruginosa* biofilms. *Antimicrob Agents Chemother*. 1994;38:2125–33.
36. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary biofilm device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. *J Clin Microbiol*. 1999;37:1771–6.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

